Lianyungang Medical (688271.SH) announced that the company plans to invest in Sichuan Jiuyi Yuan Particle Technology Co., Ltd. with its own funds...
According to the announcement released by Lianyungang Medical (688271.SH), the company plans to invest in Sichuan Jiuyi Yuan Particle Technology Co., Ltd. (referred to as "Jiuyi Yuan") with its own funds, acquiring 10% of its equity after the capital increase at a transaction price of 0.12 billion yuan.
It is reported that Jiuyi Yuan is one of the few cyclotron production enterprises. Its main products are accelerators with different energy levels, such as 7MeV, 11MeV, and 20MeV. Medical cyclotrons are mainly used to prepare positron-emitting radioactive isotopes for PET (Positron Emission Tomography) imaging, which is one of the essential core equipment for nuclear medicine diagnosis and treatment.
PET is a modern large-scale medical imaging device that firstly introduces positron-emitting radioactive drugs with selective aggregation characteristics into the patient's body through respiration or intravenous injection. It marks specific organs or lesion locations. Then, PET imaging is used for the early detection and diagnosis of major diseases such as tumors, coronary heart disease, and neurological and psychiatric diseases. It has irreplaceable advantages in the treatment of malignant tumors, cardiovascular and cerebrovascular diseases and other diseases compared to other drugs.
Before domestic products were launched, domestic medical cyclotrons relied on imports, and equipment prices were high. Jiuyi Yuan successfully developed the first domestically produced medical cyclotron in China and launched it to the market, breaking the long-standing market monopoly by foreign products in China. Radioactive isotopes are the basis of nuclear medicine diagnosis and treatment. With the promotion of precise medical concept, PET imaging, as an important component of molecular imaging technology, will play an increasingly important role in the diagnosis of relevant diseases. After careful study, the company decided to invest in Jiuyi Yuan. This investment will further promote cooperation between the two parties in the domestic and overseas molecular imaging fields.